Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can avastin stop ovarian cancer after Second-Look surgery?

NCT ID NCT02884648

First seen Feb 06, 2026 · Last updated Jun 16, 2026 · Updated 24 times

Summary

This study tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that is still present after initial treatment and found during a second-look surgery. The trial enrolled 35 adults with advanced-stage cancer who had already received standard chemotherapy and surgery. Researchers measure how long participants live without their cancer getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

The condition(s) this trial relates to.

fallopian tube neoplasm female reproductive organ cancer ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.